Compounded GLP-1 “essentially a copy” rule: a 2026 guide

01

Why FDA clarified the rule in April 2026

FDA’s April 1, 2026 statement addressed compounding as national GLP-1 supply stabilized. The agency reminded compounders that sections 503A and 503B provide exemptions from specified federal requirements only when every condition of the relevant section is met. Restrictions on products that copy available approved drugs are part of those conditions.

The phrase essentially a copy is narrower and more technical than a consumer comparison such as generic, similar, personalized, or compounded. It asks how the compounded product compares with commercially available or approved products under the applicable statutory framework. It does not decide whether the product is medically appropriate, whether the pharmacy followed every requirement, or whether an advertisement is fair.

This guide explains the verification questions raised by that statement. It does not provide legal advice, determine whether a particular prescription complies with law, or recommend an approved or compounded GLP-1 product.

02

How FDA describes the 503A comparison

Under section 503A, qualifying compounding generally occurs for an identified individual patient based on a valid prescription. FDA’s final guidance says a compounder must not regularly or in inordinate amounts make drug products that are essentially copies of a commercially available product.

FDA’s 2026 clarification describes the core comparison as the same active ingredient or ingredients in the same, similar, or easily substitutable strength when the commercially available product can be used by the same route prescribed for the compounded product. The approved product’s labeled route is not the only question; the agency’s wording focuses on whether it can be used by that route.

An exception may apply when the prescriber determines that a change in the compounded product produces a significant difference for the identified patient and documents that determination. That is not a general declaration that a clinic’s formula is better, more personalized, or medically necessary for everyone.

• →Identify the exact active ingredient and chemical form.
• →Compare strength or concentration and route.
• →Confirm the commercially available product considered.
• →Ask who documented the patient-specific significant difference.
• →Do not infer compliance from a marketing adjective.

03

Why an added ingredient does not automatically avoid the rule

Some advertisements distinguish a compounded GLP-1 product by adding vitamin B12 or another active ingredient. FDA’s April clarification directly addresses combinations. The agency says it may consider a compounded product essentially a copy when its active ingredients correspond to two or more commercially available products in the same, similar, or easily substitutable strengths and the available products can be used by the same route.

FDA gives a semaglutide-plus-cyanocobalamin example. It explains that the agency may consider the combination a copy when both are used by the same route and the ingredient amounts are within 10 percent of the strengths in the respective commercially available products, unless the documented patient-specific significant-difference condition applies.

The 10 percent example should not be turned into a consumer dosing rule, a formula design instruction, or a promise that any difference above that number qualifies. It appears in FDA’s enforcement-policy explanation and must be read with the full guidance and facts. Consumers should ask for the prescriber’s product-specific reasoning rather than infer legality or benefit from the presence of an additive.

04

How 503B and shortage status change the questions

Section 503B applies to registered outsourcing facilities and uses a separate restriction on compounding products that are essentially copies of one or more FDA-approved drugs. FDA’s final 503B guidance explains that the analysis is not identical to 503A. An outsourcing facility’s registration does not make its drugs FDA-approved.

Shortage status can matter. FDA explains that the identical-or-nearly-identical restriction for 503B generally does not apply in the same way while the approved drug is on FDA’s shortage list, and bulk-substance use has its own shortage-related condition. When a shortage resolves, FDA policy can allow limited time for orders already received, but new and existing orders are treated differently.

Check the exact active ingredient in FDA’s live shortage database immediately before relying on a claim. As of this article’s review, FDA’s 2026 clarification stated that semaglutide and tirzepatide were not on the shortage list, while the current shortage database separately listed liraglutide injection in shortage. One product’s status does not establish the status of every GLP-1 drug or every presentation.

• →Verify the legal name and address of the actual compounding facility.
• →Check whether the seller claims 503A or 503B.
• →Search the exact active ingredient and presentation in FDA’s shortage database.
• →Record the date because shortage status can change.

05

What the four-prescription statement does—and does not—mean

FDA’s April 2026 page restates a 503A enforcement policy: at that time, the agency did not intend to take action for the regularly or inordinate amounts provision when a compounder filled four or fewer prescriptions of an essentially copied drug product in a calendar month. The statement concerns FDA’s enforcement approach to that defined provision.

It is not a blanket authorization for four prescriptions, a patient entitlement, an approval threshold, or a way for a national telehealth program to divide mass production among locations. Other conditions of section 503A and state law still apply, and the policy can be revised.

A clinic should not market the number as evidence that its product is FDA-approved, safer, or exempt from verification. Consumers generally cannot establish a pharmacy’s calendar-month volume from an advertisement, so the relevant step is to identify the pharmacy and ask for a clear explanation of the product and pathway.

06

A consumer checklist for compounded GLP-1 claims

Start by separating the clinic, prescribing medical group, dispensing pharmacy, and any outsourcing facility. Record the exact product name, ingredient form, concentration, route, label, lot, beyond-use date, and whether the advertisement describes an FDA-approved or compounded drug.

Ask which available approved product was considered and what patient-specific change the prescriber documented. A generic statement that every patient benefits from a vitamin, a different concentration, or a custom dose does not show the individualized determination described in FDA’s 503A policy. Do not request a formula or adjust a prescription based on this article.

Review FDA’s current GLP-1 safety page for warnings about unapproved products, salt forms, dosing errors, adverse-event reports, fraudulent labeling, and shipping temperature. Those concerns are separate from the copy analysis and require their own verification. Discuss product choice, administration, adverse effects, and switching with an appropriately licensed clinician and dispensing pharmacist.

• →Who prescribes, and in which state is the patient located?
• →Which legal pharmacy or facility compounds and dispenses?
• →What exact active ingredient form and route appear on the label?
• →What current FDA shortage record applies?
• →What patient-specific difference did the prescriber document?
• →Where is the direct source for any regulatory claim?